Pidilizumab
Pidilizumab
Pidilizumab (pronounced as pih-dih-LIZ-uh-mab) is a monoclonal antibody designed for the treatment of cancer. It is a type of immunotherapy that targets and binds to the PD-1 receptor on T cells, blocking the PD-1/PD-L1 pathway and thereby enhancing the immune response against cancer cells.
Etymology
The name "Pidilizumab" is derived from the International Nonproprietary Names (INN), where "p" stands for peptide, "idi" for idiotype, "lizu" for lizard, and "mab" for monoclonal antibody. The "lizard" part of the name is a tribute to the cold-blooded animals' strong immune system.
Related Terms
- Monoclonal Antibodies: These are antibodies made by identical immune cells that are all clones of a unique parent cell. Monoclonal antibodies can have monovalent affinity, binding only to the same epitope.
- Immunotherapy: This is a type of cancer treatment that helps your immune system fight cancer. It is a type of biological therapy.
- Programmed cell death protein 1 (PD-1): This is a protein on the surface of cells that has a role in regulating the immune system's response to the cells of the human body by down-regulating the immune system and promoting self-tolerance by suppressing T cell inflammatory activity.
- T cells: These are a type of white blood cell that are one of the key components of the immune system. They are responsible for a variety of immune responses in the body.
External links
- Medical encyclopedia article on Pidilizumab
- Wikipedia's article - Pidilizumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski